884495-36-7

Usage

Uses

6-Chloro-3-formyl-2-picoline can be used as plasma kallikrein inhibitors.

InChI:InChI=1/C7H6ClNO/c1-5-6(4-10)2-3-7(8)9-5/h2-4H,1H3

Upstream product

• 132606-40-7 3-bromo-6-chloro-2-methyl-pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 66909-36-2 6-chloro-2-methyl-3-pyridinecarbonitrile 

Downstream Products

• 926296-40-4 [4-(5-formyl-6-methyl-pyridin-2-ylsulfanyl)-phenyl]-acetic acid methyl ester 
• 926305-03-5 [4-(5-formyl-6-methyl-pyridin-2-yloxy)-phenylsulfanyl]-acetic acid tert-butyl ester 
• 926303-58-4 6-(4-bromo-2-methyl-phenylsulfanyl)-2-methyl-pyridine-3-carbaldehyde 
• 926305-17-1 N-cyclopropyl-4-(5-formyl-6-methyl-pyridin-2-yloxy)-benzamide 
• 1150617-08-5 N-{4-[(5-formyl-6-methyl-2-pyridinyl)thio]phenyl}methanesulfonamide 
• 1150617-12-1 N-[2-(ethyloxy)ethyl]-4-[(5-formyl-6-methyl-2-pyridinyl)amino]-3-methylbenzamide 
• 1093879-95-8 (6-chloro-2-methylpyridin-3-yl)methanol 
• 7631-86-9 SiO₂ 
• 439111-18-9 1-(6-chloro-2-methylpyridin-3-yl)ethan-1-one 
• 106984-91-2 6-oxo-1,6-dihydropyridine-3-carbaldehyde 

Relevant academic research and scientific papers

NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

This application describes a nitrogen heteroaryl derivative having CSF1R inhibitory activity, and a preparation method therefor and an application thereof. Compounds in the present invention has a structure represented by formula (I) as below, and the definition on substituents is as stated in the description and the claims. The compounds in the this application can be widely applied to preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease, or metastatic disease, in particular ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, metastasis of primary tumor sites, or osseous metastatic cancer, and a new generation of CSF1R inhibitor drugs is expected to be developed.

NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY

The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).